The cancer vaccine market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising number of cancer diagnoses, heightened awareness of cancer vaccines, ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...

The long-term survival of patients is dependent upon the complete macroscopic resection of the tumor (R0, R1). [53] Patients with grossly incomplete resections (R2) survive less than 1 year, [11 ...

An update from OncoSil Medical Ltd ( ($AU:OSL) ) is now available. OncoSil Medical Limited has announced an investor webinar to discuss recent ...

Pancreatic cancer can cause back pain that spreads from the abdomen. It often affects the middle of the back and may feel like a dull ache. For some people, the pain may come and go. Pancreatic ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

published results of the registrational phase 2 eNRGy trial for Bizengri ® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

published results of the registrational phase 2 eNRGy trial for Bizengri ® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non-small cell lung ...